Prospective study on mental status in RA patients on tumour necrosis factor vs non-tumour necrosis factor-targeted therapies after achieving treatment target
Authors' conclusion
In RA patients who achieved treatment targets, non-TNF-targeted therapies, particularly IL-6Ri and JAKi, significantly improved anxiety and depression at 1 year compared with TNFi.
Study context
- Population
- RA patients who achieved low disease activity (LDA) or remission using b/tsDMARDs363 treatment courses
- Participants
- 328 patients
- Exposure
- Non-TNF-targeted therapies vs tumour necrosis factor inhibitor (TNFi) in RA patients who achieved LDA or remission
- Outcome
- Clinically meaningful improvement (exceeding minimal clinically important difference (MCID) threshold) in Hospital Anxiety and Depression Scale (HADS) anxiety (HADS anxiety (HADS-A)) or depression (HADS-D)
- Follow-up
- 1 year
Methodological detailspropensity score overlap weighting, weighted generalized linear models
- Propensity score overlap weighting
- Weighted generalized linear models
Main finding
As reported in the abstract
Non-TNF-targeted therapies vs TNFiRelative risk (95% CI)
Clinically meaningful improvement in HADS-A
1.80(1.25–2.59)
Clinically meaningful improvement in HADS-D
1.44(1.02–2.06)
Observational data: associations, not effects.
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Prospective study on mental status in RA patients on tumour necrosis factor vs non-tumour necrosis factor-targeted therapies after achieving treatment target. Rheumatology (Oxford). Published 7 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →